HONG KONG SAR - Media OurReach Newswire - 13 November 2025 - Citi hosted its 2025 China Conference this week and released an updated research report on Fosun International (00656.HK), reiterating its "Buy" rating and raising the target price to HK$6.5. Citi remains positive on Fosun's business streamlining and core business-focused strategy. Following a series of recent meetings with Fosun's management team, Citi noted that the discussions reflected a clear strategic direction. Management has indicated that Fosun will continue to focus on its core businesses, deepen its global presence, and continue to step up innovation efforts. Citi also notes Fosun's ongoing efforts to optimize its financial structure and highlights its firm commitment to deleveraging and divesting non-core assets. Fosun's business streamlining approach will not only enhance financial resilience but also sharpen the Group's strategic focus on core businesses to unlock long-term value. UBS, in its latest research report, also notes Fosun's proactive steps to dispose non-core assets, optimize its asset portfolio, and increase cash flow amid improving equity market sentiment and valuation, thus raising the target price for Fosun International. In fact, multiple domestic and international securities firms, including Citi, Industrial Securities, Kaiyuan Securities, Huaxi Securities, SDIC Securities, China Securities, and Founder Securities, currently hold "Buy" or "Overweight" ratings on Fosun International, with target prices ranging from HK$6.5 to HK$7.5. They are confident in Fosun's solid business resilience and innovation-driven growth. Citi highlights that Fosun's health and insurance businesses will provide long-term profit momentum for the Group, while securities firms such as Industrial Securities and Huaxi Securities remain upbeat on the sustained breakthroughs in Fosun's core cultural tourism and consumer businesses. Powered by continuous innovation, Fosun's Health segment has achieved multiple breakthroughs in the field of innovative drugs, earning strong endorsements from securities firms. Among which, HANSIZHUANG, an anti-PD-1 monoclonal antibody independently developed by Fosun, has become the world's first anti-PD-1 monoclonal antibody approved for the first-line treatment of small cell lung cancer (SCLC). To date, it has been approved for marketing in nearly 40 countries and regions, including China, the European Union, the United Kingdom, Singapore, and India. Additionally, HLX43, a PD-L1-targeting antibody-drug conjugate (ADC) independently developed by Fosun, is undergoing clinical studies for solid tumors such as non-small cell lung cancer and thymic carcinoma in countries including China, the United States, and Australia. Currently, no PD-L1 ADC has been approved globally, positioning HLX43 as a potential highly effective and safe broad-spectrum anticancer drug. In the insurance business, Fidelidade maintained steady growth in 2024. It recorded a 12.7% year-on-year increase in insurance income, with net profit for the full year reaching EUR253 million. In July 2025, S&P assigned Fidelidade an "A" rating. It anticipates that, over the next two years, Fidelidade will continue to maintain its leading positions in both Portugal and international markets, and sustain robust capital strength and profitability to achieve steady growth. In the cultural tourism business, during the National Day and Mid-Autumn Festival holidays in 2025, Taicang Alps International Resort welcomed over 50,000 visitors, while Lijiang Club Med Resort reported full occupancy for three consecutive days. In addition, the six resorts of Club Med Urban Oasis and Club Med Joyview saw their average daily room rates increase nearly 10% year-on-year. In particular, the Heilongtan resort sustained an occupancy rate above 94% for six consecutive days, driving a 36% year-on-year increase in total business volume for Club Med in China and a 213% surge in inbound tourists. Meanwhile, Atlantis Sanya achieved a 20% year-on-year increase in average daily room rate, further consolidating its leadership in the high-end resort market. In the consumer business, securities firms note that Yuyuan is accelerating adjustments to its overall operating strategy. While short-term earnings are experiencing pressure, the jewelry segment's results indicate the company has entered the latter stage of its adjustment cycle, with core businesses gradually recovering. Citi also highlights the positive sequential momentum in Yuyuan's gold and jewelry business, demonstrating the resilience of Fosun's consumer portfolio. The market broadly anticipates that with a moderate recovery in the consumer market, the establishment of the Shanghai International Jewelry & Style District, and the deepening of global presence, Yuyuan is poised to establish new growth drivers in core areas such as jewelry fashion and commercial operations, unlocking greater growth potential. Fosun...